uniQure (QURE) Shares Climb 11.8% on AMT-130 Gene Therapy Update

uniQure (QURE) shares climbed 11.8% on June 17, 2026, following a positive update regarding its AMT-130 gene therapy program for Huntington's disease. The company reported encouraging progress in its ongoing clinical trials, sparking investor optimism. Other biotech companies also posted significant gains. Longevity AI (LNAI) shares rose 10.9% after announcing it remains on track to meet fourth-quarter 2026 milestones for its AI-driven drug discovery initiatives. Fathom Pharma (FTH) saw its stock increase 9.5%, with the company anticipating the release of clinical data for its lead oncology candidate in Q4 2026. Eledon Pharmaceuticals (ELTX) also experienced an 8.3% rise in its share price.